Celldex Retained Earnings vs Capital Stock Analysis
CLDX Stock | USD 40.86 1.51 3.84% |
Celldex Therapeutics financial indicator trend analysis is way more than just evaluating Celldex Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Celldex Therapeutics is a good investment. Please check the relationship between Celldex Therapeutics Retained Earnings and its Capital Stock accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.
Retained Earnings vs Capital Stock
Retained Earnings vs Capital Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Celldex Therapeutics Retained Earnings account and Capital Stock. At this time, the significance of the direction appears to have pay attention.
The correlation between Celldex Therapeutics' Retained Earnings and Capital Stock is -0.8. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Capital Stock in the same time period over historical financial statements of Celldex Therapeutics, assuming nothing else is changed. The correlation between historical values of Celldex Therapeutics' Retained Earnings and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Celldex Therapeutics are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Retained Earnings i.e., Celldex Therapeutics' Retained Earnings and Capital Stock go up and down completely randomly.
Correlation Coefficient | -0.8 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Capital Stock
The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.Most indicators from Celldex Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Celldex Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.At this time, Celldex Therapeutics' Tax Provision is fairly stable compared to the past year. Enterprise Value is likely to rise to about 1.8 B in 2024, whereas Selling General Administrative is likely to drop slightly above 29.4 M in 2024.
2023 | 2024 (projected) | Extraordinary Items | 17.2M | 15.3M | Reconciled Depreciation | 2.9M | 3.1M |
Celldex Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Celldex Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Celldex Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 122.9M | 235.8M | 444.7M | 352.7M | 465.6M | 488.9M | |
Other Current Liab | 2.0M | 3.4M | 1.6M | 13.8M | 26.0M | 27.3M | |
Total Current Liabilities | 11.6M | 14.2M | 16.5M | 18.6M | 31.1M | 32.7M | |
Total Stockholder Equity | 94.0M | 209.4M | 419.5M | 326.2M | 429.2M | 450.6M | |
Property Plant And Equipment Net | 4.0M | 3.8M | 3.6M | 3.7M | 6.6M | 5.7M | |
Net Debt | (7.6M) | (40.4M) | (36.1M) | (25.4M) | (32.3M) | (33.9M) | |
Retained Earnings | (1.0B) | (1.1B) | (1.1B) | (1.3B) | (1.4B) | (1.3B) | |
Cash | 11.2M | 43.8M | 39.1M | 29.4M | 34.8M | 31.5M | |
Non Current Assets Total | 56.2M | 38.0M | 33.8M | 35.0M | 33.9M | 31.0M | |
Cash And Short Term Investments | 64.4M | 194.4M | 408.3M | 305.0M | 421.7M | 442.8M | |
Common Stock Shares Outstanding | 14.5M | 29.6M | 42.9M | 46.9M | 48.4M | 50.9M | |
Liabilities And Stockholders Equity | 122.9M | 235.8M | 444.7M | 352.7M | 465.6M | 488.9M | |
Non Current Liabilities Total | 17.3M | 12.3M | 8.7M | 7.9M | 5.3M | 5.1M | |
Other Current Assets | 2.3M | 3.4M | 2.6M | 12.7M | 5.5M | 2.9M | |
Other Stockholder Equity | 1.1B | 1.3B | 1.6B | 1.6B | 1.8B | 1.9B | |
Total Liab | 28.9M | 26.5M | 25.2M | 26.5M | 36.5M | 25.7M | |
Property Plant And Equipment Gross | 7.5M | 7.3M | 27.6M | 29.4M | 29.0M | 30.5M | |
Total Current Assets | 66.7M | 197.8M | 410.8M | 317.7M | 431.7M | 453.3M | |
Accumulated Other Comprehensive Income | 2.6M | 2.6M | 1.9M | 1.3M | 3.3M | 3.5M | |
Net Receivables | 1.0M | 1.8M | 172K | 347K | 4.5M | 4.8M | |
Inventory | (1.0M) | (1.8M) | (172K) | (347K) | 1.0 | 0.95 | |
Accounts Payable | 1.2M | 1.0M | 1.2M | 3.3M | 3.5M | 3.7M | |
Short Long Term Debt Total | 3.7M | 3.5M | 3.0M | 4.0M | 2.5M | 4.6M | |
Short Term Debt | 1.9M | 1.3M | 1.7M | 1.4M | 1.6M | 2.6M | |
Common Stock Total Equity | 12K | 17K | 40K | 47K | 54.1K | 65.1K | |
Common Stock | 12K | 17K | 40K | 47K | 56K | 64.5K | |
Intangible Assets | 52.2M | 34.2M | 30.3M | 31.3M | 27.2M | 34.2M | |
Current Deferred Revenue | 2.5M | 6.5M | 8.5M | 12M | 10.8M | 10.3M | |
Other Liab | 15.6M | 10.1M | 7.4M | 5.3M | 6.1M | 5.8M | |
Property Plant Equipment | 4.0M | 7.3M | 6.5M | 7.7M | 7.0M | 7.2M | |
Short Term Investments | 53.2M | 150.6M | 369.1M | 275.5M | 386.9M | 406.2M | |
Net Tangible Assets | 45.3M | 178.7M | 392.3M | 299.0M | 343.9M | 361.1M | |
Retained Earnings Total Equity | (962.4M) | (1.0B) | (1.1B) | (1.1B) | (1.0B) | (1.1B) | |
Capital Surpluse | 1.1B | 1.1B | 1.3B | 1.6B | 1.8B | 1.0B | |
Non Current Liabilities Other | 17.3M | 10.1M | 7.4M | 5.3M | 4.4M | 4.2M |
Celldex Therapeutics Investors Sentiment
The influence of Celldex Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Celldex. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Celldex Therapeutics' public news can be used to forecast risks associated with an investment in Celldex. The trend in average sentiment can be used to explain how an investor holding Celldex can time the market purely based on public headlines and social activities around Celldex Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Celldex Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Celldex Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Celldex Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Celldex Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Celldex Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Celldex Therapeutics' short interest history, or implied volatility extrapolated from Celldex Therapeutics options trading.
Pair Trading with Celldex Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celldex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celldex Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Celldex Stock
0.64 | VKTX | Viking Therapeutics | PairCorr |
The ability to find closely correlated positions to Celldex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Celldex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Celldex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Celldex Therapeutics to buy it.
The correlation of Celldex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Celldex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Celldex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Celldex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.Note that the Celldex Therapeutics information on this page should be used as a complementary analysis to other Celldex Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Complementary Tools for Celldex Stock analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Celldex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Celldex Therapeutics. If investors know Celldex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Celldex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.92) | Revenue Per Share 0.142 | Quarterly Revenue Growth 1.561 | Return On Assets (0.22) | Return On Equity (0.37) |
The market value of Celldex Therapeutics is measured differently than its book value, which is the value of Celldex that is recorded on the company's balance sheet. Investors also form their own opinion of Celldex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Celldex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Celldex Therapeutics' market value can be influenced by many factors that don't directly affect Celldex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Celldex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Celldex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Celldex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.